title: Cytokine activation of natural killer cells.
abstract: CD3(-)CD56(+) natural killer (NK) cells can kill various tumors in a non major histocompatibility complex (MHC)-restricted fashion. Recent advances have been made in the application of NK cells for the treatment of patients with acute myelogenous leukemia (AML). Allogeneic donor-derived NK cells can be activated in vitro and infused into patients receiving stem cell transplants. We describe in this chapter the method to activate NK cells with cytokines and to ascertain their degree of activation.
authors.affiliation: Division of Asthma, Allergy, and Rheumatology, Department of Pediatrics, Chang Gung Memorial Hospital, Kweishan, Taoyuan, Taiwan.
authors.forename: Syh-Jae
authors.initials: SJ
authors.lastname: Lin
authors.forename: Pei-Tzu
authors.initials: PT
authors.lastname: Lee
authors.forename: Ming-Ling
authors.initials: ML
authors.lastname: Kuo
mesh_terms: D002469:Cell Separation / Q000379:methods*; D005434:Flow Cytometry; D006801:Humans; D019409:Interleukin-15 / Q000276:immunology* / Q000494:pharmacology; D007376:Interleukin-2 / Q000276:immunology* / Q000494:pharmacology; D007694:Killer Cells, Natural / Q000166:cytology* / Q000187:drug effects / Q000276:immunology*; D008213:Lymphocyte Activation / Q000187:drug effects
chemical_list: D019409:Interleukin-15; D007376:Interleukin-2